Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.48 |
| ▸ | CDK1 | P06493 | 11/20 | 0.48 |
| ▸ | KDR | P35968 | 7/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CCND1 | P24385 | 2/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CCNH | P51946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866210 | 0.90 | RAB9A (0.52) | CDK2CDK1KDRCHEK1NTRK2 | |
| SCHEMBL4023231 | 0.90 | CDK2 (0.49) | CDK2CDK1KDRCHEK1NTRK2 | |
| SCHEMBL13897807 | 0.85 | CDK1 (0.47) | CDK2CDK1KDRCHEK1NTRK2 | |
| SCHEMBL3864679 | 0.84 | ULK1 (0.39) | CDK2CDK1KDRCHEK1NTRK2 | |
| SCHEMBL4018601 | 0.83 | CDK1 (0.50) | CDK2CDK1KDRCA2CCNB1 | |
| SCHEMBL13897805 | 0.83 | CDK1 (0.46) | CDK2CDK1KDRCHEK1NTRK2 | |
| SCHEMBL13897693 | 0.82 | CDK1 (0.46) | CDK2CDK1KDRCHEK1NTRK2 | |
| SCHEMBL3865627 | 0.82 | CDK1 (0.39) | CDK2CDK1KDRCHEK1NTRK2 | |
| SCHEMBL13897680 | 0.82 | CDK1 (0.46) | CDK2CDK1KDRCHEK1NTRK2 | |
| SCHEMBL13897804 | 0.81 | CDK1 (0.44) | CDK2CDK1KDRCHEK1NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | claimed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | claimed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | CDK2 105/4885CDK1 237/4885KDR 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.